<SEC-DOCUMENT>0001279569-19-000750.txt : 20190328
<SEC-HEADER>0001279569-19-000750.hdr.sgml : 20190328
<ACCEPTANCE-DATETIME>20190328171709
ACCESSION NUMBER:		0001279569-19-000750
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190328
FILED AS OF DATE:		20190328
DATE AS OF CHANGE:		20190328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		19712946

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of March 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410 </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway, Vancouver,
British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F &#9746; Form 40-F
&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 3%">&nbsp;</TD>
    <TD STYLE="width: 89%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ex991.htm"><FONT STYLE="font-size: 10pt">News release dated March 28, 2019: ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant
Prostate Cancer.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT>
        <FONT STYLE="font-size: 10pt">P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT> <FONT STYLE="font-size: 10pt">I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 107%">Date: March 28, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT> <FONT STYLE="font-size: 10pt">W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED MARCH 28, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.5</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="essalogo.jpg" ALT="" STYLE="width: 190px; height: 90px">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA Pharma Announces Nomination of EPI-7386
as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">HOUSTON and VANCOUVER, March 28, 2019 /CNW/
- ESSA Pharma Inc.&nbsp;(TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment
of prostate cancer, today announced the nomination of EPI-7386 as the lead clinical candidate for the treatment of metastatic castration-resistant
prostate cancer (&quot;mCRPC&quot;). EPI-7386 is a novel drug candidate that inhibits the N-terminal domain of the androgen receptor.
Through this novel mechanism of action, EPI-7386 displays activity <I>in vitro</I> in numerous prostate cancer models including
models where current antiandrogens are inactive. Compared to ESSA's first generation compound, ralaniten acetate, EPI-7386 is significantly
more potent, metabolically stable and more effective in preclinical studies. In addition, EPI-7386 has demonstrated a favorable
tolerability profile in all animal studies of the compound conducted to date. IND-enabling studies are currently underway, and
ESSA expects to enter clinical studies with EPI-7386 in the first quarter of 2020. &nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">As recently presented at the 2019 Genitourinary
Cancers Symposium, EPI-7386 demonstrates <I>in vitro</I> cellular potency against the androgen receptor in a similar range to the
leading antiandrogens, bicalutamide and enzalutamide. Importantly, EPI-7386 shows activity in numerous <I>in vitro </I>models of
antiandrogen resistance driven by the AR-V7 splice variant of the androgen receptor while enzalutamide is inactive. In addition,
EPI-7386 is metabolically stable in liver microsome and hepatocyte preparations and shows a favorable pharmacokinetic profile in
mice, exhibiting significant exposure and a long half-life. Lastly, EPI-7386 (60 mg/kg) displayed comparable activity to enzalutamide
(30 mg/kg) in a prostate cancer LNCaP xenograft mouse model in which enzalutamide mouse exposure was estimated to be twice the
clinical exposure of enzalutamide in humans.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;We are excited to announce the nomination
of EPI-7386 as our lead clinical candidate for the treatment of mCRPC,&quot; said David Parkinson, President and Chief Executive
Officer of ESSA. &quot;EPI-7386 represents a novel approach to targeting the androgen receptor, one of the most validated targets
in oncology. We look forward to bringing this novel drug candidate to patients with mCRPC who have no other treatment options.&quot;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About ESSA Pharma Inc.</B><BR>
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant
prostate cancer (&quot;CRPC&quot;) in patients whose disease is progressing despite treatment with current therapies. ESSA believes
that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit
from hormone-based therapies, by disrupting the androgen receptor (&quot;AR&quot;) signaling pathway that drives prostate cancer
growth and by preventing AR transcriptional activity by binding selectively to the N-terminal domain (&quot;NTD&quot;) of the AR.
A functional NTD is essential for transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated the capability
to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded in 2009.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA proprietary compounds, otherwise known
as aniten compounds, bind to the N-terminal domain of the androgen receptor (&quot;AR&quot;).&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Prostate Cancer</B><BR>
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide
(Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen
action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical
or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally
represents a transition to the lethal variant of the disease, metastatic CPRC (&quot;mCRPC&quot;), and most patients ultimately
succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional
treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including
abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally
experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both
in vitro and in vivo animal studies, ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking
tumor growth when current therapies are no longer effective.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward-Looking Statement Disclaimer</B><BR>
This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;look forward&quot;, &quot;anticipate&quot; and, &quot;believe&quot;, and statements that an action or event
&quot;is expected&quot;, &quot;should&quot;, or &quot;will&quot; be taken or occur, or other similar expressions and includes,
but is not limited to, statements regarding pre-clinical characteristics and potential performance of the EPI-7386 drug candidate,
including potency, metabolic stability, effectiveness, tolerability, exposure and half-life length, the expected timeline for EPI-7386
entering clinical trials, and beliefs about ESSA's proprietary compounds significantly expanding the interval of time in which
patients suffering from CRPC can benefit from hormone-based therapies.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking statements and information
are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict,
and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied
thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such
statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. In making forward-looking statements, ESSA may make various material assumptions, including but not limited
to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and economic conditions.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking information is developed based
on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated
December 13, 2018 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website
at www.sedar.com or ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR and EDGAR
profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements
are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other
circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned
against attributing undue certainty to forward-looking statements.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_002.jpg" ALT="Cision" STYLE="height: 12px; width: 12px">View
original content to download multimedia:http://www.prnewswire.com/news-releases/essa-pharma-announces-nomination-of-epi-7386-as-lead-clinical-candidate-in-metastatic-castration-resistant-prostate-cancer-300820449.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/March2019/28/c4040.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001633932</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Peter Virsik, Chief Operations Officer,
ESSA Pharma Inc., Contact: (778) 331-0962; Investor Relations Contact: Alan Lada, Solebury Trout, (617) 221-8006, alada@soleburytrout.com</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 17:01e 28-MAR-19</P>



<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJM&=)VD=5'$0JJ\2W11161L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?*NI?\A:]_Z^)/\ T(U]55\JZE_R%KW_
M *^)/_0C7IY9O+Y'DYKM'YE:BBKFEZ9=ZSJ4.GV2*]S,2$5F"@X!)Y/L#7K-
MI*[/&2;=D4Z*[+_A5GBS_GR@_P# E*/^%6>+/^?*#_P)2LOK%'^9&WU6M_*S
MC:*[+_A5GBS_ )\H/_ E*/\ A5GBS_GR@_\  E*/K%'^9!]5K?RLXVBNR_X5
M9XL_Y\H/_ E*/^%6>+/^?*#_ ,"4H^L4?YD'U6M_*SC:](^#'_(R:A_UZ?\
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MY'SA17H^K?![5K8L^EWD%['V23]V_P#@?S%<5J/A[6=()%_IEU !_&T9*_\
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MB;GDOQEUO+V.AQ-P/])G /U"#_T(_E7E%:?B+5WU[Q#?:DV<3RDH#V0<*/R
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MJ<ZZGNY;5YJ?(^A)1117 >D%%%% !1110 4444 %%%% !1110 4444 %%%%
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M[6_V3WKYQU72KW1=0DL=0@:&=.H/1AZ@]P?6OJ>LCQ!X:TSQ+9?9M1@#[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ,  P# 2(  A$! Q$!_\0
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?L94\=#@5IJH50HZ 8%8TXM3DWU.BK.+I02Z>7ZG_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
